REGENXBIO (NASDAQ:RGNX) Stock Rating Reaffirmed by HC Wainwright

HC Wainwright reissued their buy rating on shares of REGENXBIO (NASDAQ:RGNXFree Report) in a research note published on Thursday, Benzinga reports. HC Wainwright currently has a $38.00 target price on the biotechnology company’s stock.

Several other equities analysts have also weighed in on RGNX. Raymond James reaffirmed an outperform rating and set a $45.00 target price on shares of REGENXBIO in a report on Wednesday, February 21st. StockNews.com raised shares of REGENXBIO from a sell rating to a hold rating in a research note on Tuesday, June 18th. Robert W. Baird lifted their target price on shares of REGENXBIO from $34.00 to $39.00 and gave the stock an outperform rating in a research note on Wednesday, March 6th. The Goldman Sachs Group started coverage on shares of REGENXBIO in a research note on Friday, June 7th. They set a buy rating and a $38.00 target price on the stock. Finally, Royal Bank of Canada raised shares of REGENXBIO from a sector perform rating to an outperform rating and lifted their target price for the stock from $20.00 to $35.00 in a research note on Friday, March 8th. Three research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. According to MarketBeat, the stock has a consensus rating of Moderate Buy and an average target price of $38.58.

Get Our Latest Report on RGNX

REGENXBIO Stock Up 1.2 %

Shares of REGENXBIO stock opened at $12.02 on Thursday. REGENXBIO has a 52 week low of $11.43 and a 52 week high of $28.80. The firm has a market capitalization of $592.11 million, a P/E ratio of -2.04 and a beta of 1.34. The company has a 50 day moving average price of $15.06 and a 200 day moving average price of $17.15.

REGENXBIO (NASDAQ:RGNXGet Free Report) last posted its quarterly earnings results on Wednesday, May 8th. The biotechnology company reported ($1.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.10). REGENXBIO had a negative return on equity of 70.72% and a negative net margin of 299.96%. The business had revenue of $15.60 million for the quarter, compared to analysts’ expectations of $23.52 million. During the same period in the prior year, the business posted ($1.53) earnings per share. The business’s quarterly revenue was down 18.3% compared to the same quarter last year. As a group, research analysts anticipate that REGENXBIO will post -3.9 earnings per share for the current fiscal year.

Insider Activity at REGENXBIO

In related news, CEO Kenneth T. Mills sold 15,000 shares of the business’s stock in a transaction dated Tuesday, May 14th. The shares were sold at an average price of $15.81, for a total value of $237,150.00. Following the sale, the chief executive officer now directly owns 408,035 shares in the company, valued at approximately $6,451,033.35. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 13.13% of the stock is owned by insiders.

Institutional Trading of REGENXBIO

Institutional investors and hedge funds have recently bought and sold shares of the business. Assenagon Asset Management S.A. purchased a new stake in REGENXBIO during the fourth quarter worth about $1,915,000. Perceptive Advisors LLC acquired a new position in shares of REGENXBIO during the fourth quarter worth about $6,146,000. Virtu Financial LLC acquired a new position in shares of REGENXBIO during the fourth quarter worth about $377,000. BNP Paribas Financial Markets grew its position in shares of REGENXBIO by 174.4% during the fourth quarter. BNP Paribas Financial Markets now owns 67,760 shares of the biotechnology company’s stock worth $1,216,000 after buying an additional 43,070 shares in the last quarter. Finally, Swiss National Bank boosted its holdings in REGENXBIO by 6.8% in the third quarter. Swiss National Bank now owns 86,000 shares of the biotechnology company’s stock valued at $1,416,000 after purchasing an additional 5,500 shares in the last quarter. 88.08% of the stock is currently owned by hedge funds and other institutional investors.

About REGENXBIO

(Get Free Report)

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.

Further Reading

Analyst Recommendations for REGENXBIO (NASDAQ:RGNX)

Receive News & Ratings for REGENXBIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO and related companies with MarketBeat.com's FREE daily email newsletter.